Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

ERA-EDTA Council, ERACODA Working Group, Alberto Ortiz, Mario Cozzolino, Danilo Fliser, Denis Fouque, Dimitrios Goumenos, Ziad A Massy, Alexander R Rosenkranz, Ivan Rychlık, Maria Jose Soler, Kate Stevens, Roser Torra, Serhan Tuglular, Christoph Wanner, Ron T Gansevoort, Raphaël Duivenvoorden, Casper F M Franssen, Marc H Hemmelder, Luuk B Hilbrands, Kitty J Jager, Marlies Noordzij, Priya Vart, Ron T Gansevoort, ERA-EDTA Council, ERACODA Working Group, Alberto Ortiz, Mario Cozzolino, Danilo Fliser, Denis Fouque, Dimitrios Goumenos, Ziad A Massy, Alexander R Rosenkranz, Ivan Rychlık, Maria Jose Soler, Kate Stevens, Roser Torra, Serhan Tuglular, Christoph Wanner, Ron T Gansevoort, Raphaël Duivenvoorden, Casper F M Franssen, Marc H Hemmelder, Luuk B Hilbrands, Kitty J Jager, Marlies Noordzij, Priya Vart, Ron T Gansevoort

Abstract

Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR <30 mL/min/1.73 m2) represent three of the four comorbidities associated with the highest mortality risk from COVID-19. The risk associated with CKD Stages 4 and 5 is higher than the risk associated with diabetes mellitus (aHR range 1.31-1.95, depending upon glycaemic control) or chronic heart disease (aHR 1.17). In another recent publication, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19. Moreover, the distribution of risk factors for COVID-19 mortality appears to be different in patients with CKD when compared with the general population. The high prevalence of CKD in combination with the elevated risk of mortality from COVID-19 in CKD necessitates urgent action for this group of patients. This article defines essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.

Keywords: COVID-19; chronic kidney disease; mortality; prevalence; renal replacement therapy; risk factor.

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.

Figures

FIGURE 1
FIGURE 1
Global prevalence of key underlying conditions associated with severe COVID-19 if infected. Prevalence by age. The four most prevalent risk factors have been selected and ranked from left to right according to the highest global prevalence at any age range (bold black line). Grey lines represent individual countries. Data from Clark et al. [5].
FIGURE 2
FIGURE 2
Risk factors for COVID-19-related death. Graph shows the five medical conditions associated with the highest HRs of death and, additionally, the risk associated with CKD G3 and the risk associated with the risk factors recognized early in the pandemic as associated with severe COVID-19 (diabetes, chronic heart disease and hypertension, in black). In red, conditions of nephrological interest. Light blue represents non-kidney risk factors present in et al. [4]. Patients with CKD G4–G5 have an eGFR <30 mL/min/1.73 m2 and patients with CKD G3 have an eGFR of 30–60 mL/min/1.73 m2.
FIGURE 3
FIGURE 3
CKD as a risk factor for COVID-19-related death in T1DM and T2DM patients in general practice. (A) The aHRs for COVID-19-related death according to type of diabetes and eGFR range. (B) The aHRs for COVID-19-related death according to type of diabetes, age and eGFR range. An eGFR ≥90 mL/min/1.73 m2 was the reference for both graphs and was considered to be 1 in each of the categories (T1DM, T2DM and age categories within) assessed. *P < 0.0001 versus eGFR ≥90 mL/min/1.73 m2; +, non-overlapping 95% CI versus eGFR ≥90 mL/min/1.73m2. Data derived from Holman et al. [20].
FIGURE 4
FIGURE 4
Risk factors for COVID-19-related death. Left graph shows the situation in subjects of the general population (as derived from the OpenSAFELY study; data from Williamson et al. [4]) and the right graph shows the situation in patients with end-stage kidney disease treated by maintenance haemodialysis (as derived from the ERACODA cohort; data derived from Hilbrands et al. [23]).

References

    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. (4 October 2020, date last accessed)
    1. Petersen E, Koopmans M, Go U. et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 2020; 20: e238–e244
    1. CNN World. Spanish 113-year-old speaks after surviving coronavirus. (5 September 2020, date last accessed)
    1. Williamson EJ, Walker AJ, Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430–436
    1. Clark A, Jit M, Warren-Gash C. et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health 2020; 8: e1003–e1017
    1. Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150
    1. Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E. et al. Clarifying the concept of chronic kidney disease for non-nephrologists. Clin Kidney J 2019; 12: 258–261
    1. Jager KJ, Kovesdy C, Langham R. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant 2019; 34: 1803–1805
    1. Foreman KJ, Marquez N, Dolgert A. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 2018; 392: 2052–2090
    1. Ortiz A, Sanchez-Niño MD, Crespo-Barrio M. et al. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem. Nefrologia 2019; 39: 29–34
    1. Zoccali C, Blankestijn PJ, Bruchfeld A. et al. Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. Nephrol Dial Transplant 2019; 34: 1112–1114
    1. Ortiz A, Covic A, Fliser D. et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831–1843
    1. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30]. Lancet 2020; 395: 496
    1. Chen T, Wu D, Chen H. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1295.
    1. Emami A, Javanmardi F, Pirbonyeh N. et al. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020; 8: e35.
    1. Henry BM, Lippi G.. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020; 52: 1193–1194
    1. Extance A. Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease? BMJ 2020; 368: m1270.
    1. Murray CJ, Ezzati M, Flaxman AD. et al. GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet 2012; 380: 2055–2058
    1. Reynolds HR, Adhikari S, Pulgarin C. et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020; 382: 2441–2448
    1. Holman N, Knighton P, Kar P. et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020; 8: 823–833
    1. Mancia G, Rea F, Ludergnani M. et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020; 382: 2431–2440
    1. Jager KJ, Kramer A, Chesnaye NC. et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 2020; doi: 10.1016/j.kint.2020.09.006
    1. Hilbrands LB, Duivenvoorden R, Vart P. et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant 2020; 35: 1973–1983
    1. Rincón A, Moreso F, López-Herradón A. et al. The keys to control a COVID-19 outbreak in a haemodialysis unit. Clin Kidney J 2020; 13: 542–549
    1. Carriazo S, Kanbay M, Ortiz A.. Kidney disease and electrolytes in COVID-19: more than meets the eye. Clin Kidney J 2020; 13: 274–280
    1. Kolhe NV, Fluck RJ, Selby NM. et al. Acute kidney injury associated with COVID-19: a retrospective cohort study. PLoS Med 2020; 17: e1003406.
    1. Chan L, Chaudhary K, Saha A. et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol 2020; doi: 10.1681/ASN.2020050615
    1. Braun F, Lütgehetmann M, Pfefferle S. et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 2020; 396: 597–598
    1. Puelles VG, Lütgehetmann M, Lindenmeyer MT. et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 2020; 383: 590–592
    1. Baigent C, Landray MJ, Reith C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181–2192
    1. Reddy S, Chitturi C, Yee J.. Vaccination in chronic kidney disease. Adv Chronic Kidney Dis 2019; 26: 7–8

Source: PubMed

3
Abonner